Using our proprietary iVAX toolkit, immunoinformatics experts at EpiVax can analyze antigen sequences and compile the results into a comprehensive report containing valuable data that can be used to prioritize and optimize these antigen sequences. This analysis incorporates epitope mapping to identify immunogenic T cell epitopes, regulatory T cell epitopes and sequences conserved across multiple strains.
The result is a detailed report providing expert interpretation of valuable data that can be used for superior vaccine designs.
Our tools allow us to strip a pathogen down to the minimal, essential antigens responsible for eliciting robust and sustained protective immunity while eliminating non-essential information that could lead to diminished protective immunity and/or immunopathology sometimes associated with whole organism vaccines. This approach may appear to handicap vaccine design because vital elements, that are normally part of a pathogen, are removed. However, this creates a valuable opportunity for one to combine this novel approach with best-in-class adjuvant and delivery technologies for optimal vaccine construction.
The PreVAX Analysis is a comprehensive in silico immunogenicity analysis covering overall and regional immunogenic potential of antigens of interest as well as an evaluation of their cross-conservation with human sequences.
To complete a PreVAX Analysis, EpiVax parses each input sequence into all possible “frames” of 9 amino acids, corresponding to the minimal length of an HLA-binding peptide. As each frame overlaps the previous by 8 amino acids, all possible frames are considered. Each frame is then assessed for its binding potential to a panel of Class I and Class II HLA alleles representing a large majority of the population.
Additional analysis is performed using our JanusMatrix algorithm to identify epitopes that may be cross-conserved with the human genome and, as a result, can elicit tolerance, also known as immune camouflage.
The Conservatrix algorithm is applied to pathogens that exhibit significant diversity amongst strains and it is used to identify 9-mer frames that are shared amongst strains of the vaccine target and report on their frequency within the dataset.
EpiVax also ranks whole antigen vaccine candidates against other known high and low immunogenic sequences based on epitope density.
In the final PreVAX Report, EpiVax summarizes these detailed findings, including easy to understand data visualization tools, to aid you in making more informed research and regulatory decisions.
The PreVAX Analysis Report can be used to support regulatory filings, increasing the likelihood of a favorable review.
We are certain that the time for incorporating this type of computational analysis into vaccine development is now and EpiVax is dedicated to applying our tools to designing safer and more effective vaccines against infectious disease, cancer and for bio-defense.
Contact us for our expert support in your aim to develop superior life saving vaccines.